Nektar Therapeutics (NASDAQ:NKTR)

3.05
BATS BZX Real-Time Price
As of 12:51pm ET
 +0.17 / +5.90%
Today’s Change
2.73
Today|||52-Week Range
15.95
-77.42%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$609.0M

Company Description

Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases. The company was founded in 1990 and is headquartered in San Francisco, CA.

Contact Information

Nektar Therapeutics
455 Mission Bay Boulevard South
San Francisco California 94158
P:(415) 482-5300
Investor Relations:
(628) 895-0661

Employees

Shareholders

Mutual fund holders74.24%
Individual stakeholders3.23%
Other institutional19.54%

Top Executives

Howard W. RobinPresident, Chief Executive Officer & Director
Jillian B. ThomsenChief Financial Officer & Senior Vice President
Jonathan ZalevskyChief Research & Development Officer
Brian L. KotzinChief Medical Officer & Senior Vice President
Mary TagliaferriSenior Vice President